As the U.S. market continues to navigate a mixed landscape, with the Nasdaq reaching new highs while the Dow slips, investors are keeping a close eye on potential Federal Reserve interest rate cuts amidst inflation concerns. In this context, penny stocks—often seen as investments in smaller or newer companies—remain an intriguing area for those seeking growth opportunities at lower price points. By focusing on stocks that combine strong financial health with solid fundamentals, investors can uncover hidden gems that may offer stability and upside potential in today's market.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Dingdong (Cayman) (DDL) | $2.27 | $456.47M | ✅ 4 ⚠️ 0 View Analysis > |
| Waterdrop (WDH) | $1.89 | $676.31M | ✅ 4 ⚠️ 0 View Analysis > |
| WM Technology (MAPS) | $1.25 | $206.93M | ✅ 4 ⚠️ 2 View Analysis > |
| Puma Biotechnology (PBYI) | $4.50 | $228.68M | ✅ 3 ⚠️ 2 View Analysis > |
| Performance Shipping (PSHG) | $1.87 | $23.87M | ✅ 4 ⚠️ 2 View Analysis > |
| Golden Growers Cooperative (GGRO.U) | $5.00 | $79.78M | ✅ 2 ⚠️ 5 View Analysis > |
| Table Trac (TBTC) | $4.88 | $23.8M | ✅ 2 ⚠️ 2 View Analysis > |
| BAB (BABB) | $0.947 | $7.05M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (LCUT) | $4.20 | $90.63M | ✅ 3 ⚠️ 3 View Analysis > |
| TETRA Technologies (TTI) | $4.83 | $639.74M | ✅ 3 ⚠️ 2 View Analysis > |
Click here to see the full list of 377 stocks from our US Penny Stocks screener.
We're going to check out a few of the best picks from our screener tool.
Erasca (ERAS)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Erasca, Inc. is a clinical-stage precision oncology company dedicated to discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers, with a market cap of approximately $439.69 million.
Operations: Erasca, Inc. currently does not report any revenue segments.
Market Cap: $439.69M
Erasca, Inc., a pre-revenue clinical-stage oncology firm with a market cap of US$439.69 million, has shown financial resilience despite ongoing losses. The company reported a reduced net loss of US$33.88 million for Q2 2025 compared to the previous year and maintains no debt while its short-term assets significantly exceed both short and long-term liabilities. With sufficient cash runway for over two years, Erasca is well-positioned financially but remains unprofitable with earnings forecasted to decline by 3.4% annually over the next three years. Recent filings include a US$500 million shelf registration, indicating potential capital-raising activities ahead.
- Unlock comprehensive insights into our analysis of Erasca stock in this financial health report.
- Review our growth performance report to gain insights into Erasca's future.
Viomi Technology (VIOT)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Viomi Technology Co., Ltd develops and sells IoT-enabled smart home products in China, with a market cap of approximately $225.77 million.
Operations: The company's revenue is primarily generated through online retailers, amounting to CN¥2.12 billion.
Market Cap: $225.77M
Viomi Technology Co., Ltd. has demonstrated substantial growth potential, with recent revenue guidance indicating a significant increase driven by strong sales in water purification equipment and favorable national subsidies. The company declared a special dividend totaling US$6 million, reflecting shareholder returns despite its volatile share price. Viomi's financial health appears robust, with short-term assets surpassing both short and long-term liabilities and more cash on hand than debt. However, the company's earnings have declined significantly over the past five years despite becoming profitable recently. Its board is experienced, though management tenure data remains insufficient for assessment.
- Click to explore a detailed breakdown of our findings in Viomi Technology's financial health report.
- Evaluate Viomi Technology's prospects by accessing our earnings growth report.
3D Systems (DDD)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: 3D Systems Corporation offers 3D printing and digital manufacturing solutions across various regions, including the Americas, EMEA, and Asia Pacific, with a market cap of $271.90 million.
Operations: The company's revenue is divided into two main segments: Healthcare, generating $181.76 million, and Industrial, contributing $231.58 million.
Market Cap: $271.9M
3D Systems Corporation, with a market cap of US$271.90 million, is navigating challenges typical of penny stocks. Despite being unprofitable and facing increased debt levels over the past five years, its short-term assets comfortably cover both short and long-term liabilities. The company recently secured a US$7.65 million contract with the U.S. Air Force for advanced 3D printing technology, highlighting its ongoing engagement in defense projects. However, legal issues persist as it faces a class action lawsuit related to misleading statements about business operations. Executive changes may impact stability but could also bring fresh perspectives to management strategies.
- Click here and access our complete financial health analysis report to understand the dynamics of 3D Systems.
- Examine 3D Systems' earnings growth report to understand how analysts expect it to perform.
Next Steps
- Gain an insight into the universe of 377 US Penny Stocks by clicking here.
- Looking For Alternative Opportunities? We've found 16 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Viomi Technology might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com